These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35906831)

  • 1. Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer.
    Maertens J; Lodewyck T; Donnelly JP; Chantepie S; Robin C; Blijlevens N; Turlure P; Selleslag D; Baron F; Aoun M; Heinz WJ; Bertz H; Ráčil Z; Vandercam B; Drgona L; Coiteux V; Llorente CC; Schaefer-Prokop C; Paesmans M; Ameye L; Meert L; Cheung KJ; Hepler DA; Loeffler J; Barnes R; Marchetti O; Verweij P; Lamoth F; Bochud PY; Schwarzinger M; Cordonnier C;
    Clin Infect Dis; 2023 Feb; 76(4):674-682. PubMed ID: 35906831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial.
    Fisher BT; Zaoutis T; Dvorak CC; Nieder M; Zerr D; Wingard JR; Callahan C; Villaluna D; Chen L; Dang H; Esbenshade AJ; Alexander S; Wiley JM; Sung L
    JAMA; 2019 Nov; 322(17):1673-1681. PubMed ID: 31688884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
    Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
    Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
    Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
    Dahlén T; Kalin M; Cederlund K; Nordlander A; Björkholm M; Ljungman P; Blennow O
    Eur J Haematol; 2016 Feb; 96(2):175-80. PubMed ID: 25880378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
    Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
    Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Trial of Caspofungin vs Triazoles Prophylaxis for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplant.
    Dvorak CC; Fisher BT; Esbenshade AJ; Nieder ML; Alexander S; Steinbach WJ; Dang H; Villaluna D; Chen L; Skeens M; Zaoutis TE; Sung L
    J Pediatric Infect Dis Soc; 2021 Apr; 10(4):417-425. PubMed ID: 33136159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
    Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
    Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study.
    Tan BH; Low JG; Chlebicka NL; Kurup A; Cheah FK; Lin RT; Goh YT; Wong GC
    Int J Infect Dis; 2011 May; 15(5):e350-6. PubMed ID: 21397541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer.
    Winston DJ; Hathorn JW; Schuster MG; Schiller GJ; Territo MC
    Am J Med; 2000 Mar; 108(4):282-9. PubMed ID: 11014720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden.
    Lundberg J; Höglund M; Björkholm M; Åkerborg Ö
    Clin Drug Investig; 2014 Jul; 34(7):483-9. PubMed ID: 24820968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
    Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
    N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain.
    Cámara R; Gozalbo I; Jurado M; Sanz J; Aragón B; Grau S
    Adv Ther; 2017 Sep; 34(9):2104-2119. PubMed ID: 28808915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome--still an open question?
    Rüping MJ; Vehreschild JJ; Cornely OA
    Leuk Lymphoma; 2010 Jan; 51(1):20-6. PubMed ID: 20017598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients at high risk of invasive fungal infections: when and how to treat.
    Rüping MJ; Vehreschild JJ; Cornely OA
    Drugs; 2008; 68(14):1941-62. PubMed ID: 18778118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: point.
    Gonzalez AV; Ullmann AJ; Almyroudis NG; Segal BH
    J Natl Compr Canc Netw; 2008 Feb; 6(2):175-82. PubMed ID: 18319049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal treatment strategies in high risk patients.
    Rüping MJ; Vehreschild JJ; Cornely OA
    Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
    Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital.
    Chan TS; Marcella SW; Gill H; Hwang YY; Kwong YL
    J Med Econ; 2016; 19(1):77-83. PubMed ID: 26366612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.
    Ananda-Rajah MR; Grigg A; Downey MT; Bajel A; Spelman T; Cheng A; Thursky KT; Vincent J; Slavin MA
    Haematologica; 2012 Mar; 97(3):459-63. PubMed ID: 22058198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.